Importantly, the ability to maintain protective immunity with only 8–11% PNP activity suggests this might be a sufficient threshold activity required for treating PNP deficiency with current allogenic HSC or future autologous HSC transplants and enzyme replacement therapies. This evidence concerns the gene PNP and hyperinsulinemic hypoglycemia, familial, 4.